(Reuters) - An advisory committee to the U.S. Food and Drug Administration recommended approval on Thursday of GlaxoSmithKline Plc’s drug mepolizumab for severe asthma in patients aged 18 and older.
The panel voted 10 to 4 against approving it in children aged 12 to 17.
The FDA is not obliged to follow the advice of its advisory panels but typically does so.
Help employers find you! Check out all the jobs and post your resume.
